Stay updated on Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now displays a revised version label: Revision: v3.3.2, replacing the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the funding-lapse notice that warned information on the page may not be up to date and directed users to opm.gov for status updates.SummaryDifference0.4%

- Check44 days agoChange DetectedNo additions or deletions were detected on the page; the study details and sections remain unchanged.SummaryDifference0.5%

- Check51 days agoChange DetectedResults for Pembrolizumab in untreated ENKTL have been posted, including the Complete Response Rate with related dates. The Study Protocol and Statistical Analysis Plan PDF is now available under Study Documents.SummaryDifference1%

- Check65 days agoChange DetectedCore content updated to show that results are now submitted/available instead of none being posted.SummaryDifference0.1%

- Check72 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

Stay in the know with updates to Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.